Sanofi and Regeneron restructure immuno-oncology collaboration for discovery, development programs
Sanofi and Regeneron Pharmaceuticals, Inc. have restructured their global Immuno-oncology Discovery and Development Agreement for new immuno-oncology cancer treatments. The 2015 agreement was scheduled to end in approximately mid-2020, and this revision provides for ongoing collaborative development of two clinical-stage bispecific antibody programs.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063